Literature DB >> 10408532

Genetic heterogeneity in Italian families with familial hemiplegic migraine.

P Carrera1, M Piatti, S Stenirri, L M Grimaldi, E Marchioni, M Curcio, P G Righetti, M Ferrari, C Gelfi.   

Abstract

OBJECTIVE: To verify linkage to chromosome 19p13, to detect mutations in the CACNA1A gene, and to correlate genetic results to their clinical phenotypes in Italian families with familial hemiplegic migraine (FHM).
BACKGROUND: FHM is an autosomal dominant disease, classified as a subtype of migraine with aura. Only a proportion of FHM patients have been associated with chromosome 19p13. Among these, four missense mutations within the CACNA1A gene in five unrelated families have been described.
METHODS: A linkage study was performed in 19 patients affected by FHM from five families by studying microsatellite markers associated with the 19p13 region. All familial and seven additional sporadic patients with FHM were analyzed to search for mutations within the CACNA1A gene by applying the double gradient-denaturant gradient electrophoresis technique.
RESULTS: Lod score values did not establish significantly linkage to chromosome 19. However, seven new genetic variants were detected: six were new polymorphisms. The seventh was a missense mutation present in family 1, and it was associated with a hemiplegic migraine phenotype without unconsciousness and cerebellar ataxia. Because this missense mutation is absent in the general population and cosegregates with the disease, it may be a pathologic mutation.
CONCLUSIONS: Genetic heterogeneity of FHM has been shown in familial and sporadic FHM patients of Italian origin. The new missense mutation-G4644T-is associated with milder clinical features compared with typical FHM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408532     DOI: 10.1212/wnl.53.1.26

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Sporadic hemiplegic migraine.

Authors:  David F Black
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  In vivo analysis of voltage-dependent calcium channels.

Authors:  Ling Liu; Theresa A Zwingman; Colin F Fletcher
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 3.  Migraine genetics: an update.

Authors:  J Haan; E E Kors; Kaate R J Vanmolkot; Arn M J M van den Maagdenberg; Rune R Frants; M D Ferrari
Journal:  Curr Pain Headache Rep       Date:  2005-06

4.  CACNA1B mutation is linked to unique myoclonus-dystonia syndrome.

Authors:  Justus L Groen; Arturo Andrade; Katja Ritz; Hamid Jalalzadeh; Martin Haagmans; Ted E J Bradley; Aldo Jongejan; Dineke S Verbeek; Peter Nürnberg; Sylvia Denome; Raoul C M Hennekam; Diane Lipscombe; Frank Baas; Marina A J Tijssen
Journal:  Hum Mol Genet       Date:  2014-10-08       Impact factor: 6.150

5.  Prolonged hemiplegic episodes in children due to mutations in ATP1A2.

Authors:  J C Jen; A Klein; E Boltshauser; M S Cartwright; E S Roach; H Mamsa; R W Baloh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05       Impact factor: 10.154

Review 6.  Genetics of headache in children: where are we headed?

Authors:  Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2008-10

Review 7.  Genetics of migraine headache in children.

Authors:  Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2007-10

8.  The familial hemiplegic migraine mutation R192Q reduces G-protein-mediated inhibition of P/Q-type (Ca(V)2.1) calcium channels expressed in human embryonic kidney cells.

Authors:  Karim Melliti; Manfred Grabner; Guy R Seabrook
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

Review 9.  Migraine: Calcium Channels and Glia.

Authors:  Marta Kowalska; Michał Prendecki; Thomas Piekut; Wojciech Kozubski; Jolanta Dorszewska
Journal:  Int J Mol Sci       Date:  2021-03-07       Impact factor: 5.923

Review 10.  Calcium channels and channelopathies of the central nervous system.

Authors:  Daniela Pietrobon
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.